药物发现
鉴定(生物学)
过程(计算)
计算机科学
风险分析(工程)
钥匙(锁)
制药工业
药品
数据科学
选择(遗传算法)
多样性(控制论)
产品(数学)
药理学
新产品开发
药物开发
生化工程
医学
业务
生物信息学
工程类
生物
营销
人工智能
计算机安全
几何学
数学
操作系统
植物
作者
JP Hughes,S. Rees,S. Barret Kalindjian,Karen L. Philpott
标识
DOI:10.1111/j.1476-5381.2010.01127.x
摘要
Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI